Cargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks for an exitnews2025-03-19T15:25:39+00:00March 19th, 2025|Endpoints News|
Regenxbio shares new Duchenne gene therapy data ahead of big readout next yearnews2025-03-19T15:14:21+00:00March 19th, 2025|Endpoints News|
Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 winnews2025-03-19T11:56:26+00:00March 19th, 2025|Endpoints News|
Roche inks $1B+ biobucks deal with Oxford BioTherapeutics for new antibody cancer targetsnews2025-03-19T11:05:26+00:00March 19th, 2025|Endpoints News|
Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drugnews2025-03-19T11:00:13+00:00March 19th, 2025|Endpoints News|
CRISPR startup Arbor Biotechnologies raises $73.9M as it nears first trialnews2025-03-18T10:30:00+00:00March 18th, 2025|Endpoints News|
AstraZeneca reports Phase 3 win for hypoparathyroidism drug eneboparatidenews2025-03-17T16:50:50+00:00March 17th, 2025|Endpoints News|
Incyte’s stock sinks as povorcitinib disappoints in hidradenitis suppurativanews2025-03-17T15:32:41+00:00March 17th, 2025|Endpoints News|
Orca Bio’s T cell therapy may help blood cancer patients avoid transplant issuesnews2025-03-17T15:16:35+00:00March 17th, 2025|Endpoints News|
GRO Biosciences, working on recoded organisms, cuts most staffnews2025-03-17T12:45:21+00:00March 17th, 2025|Endpoints News|
